Black Diamond Therapeutics Inc Cash Flow Conversion Efficiency
Black Diamond Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has a cash flow conversion efficiency ratio of -0.074x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.14 Million) by net assets ($96.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Black Diamond Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of Black Diamond Therapeutics Inc from 2017 to 2025. This chart illustrates how Black Diamond Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Black Diamond Therapeutics Inc stock quote for real-time trading data and today's change.
Black Diamond Therapeutics Inc Cash Flow Conversion Ratio Explained
Black Diamond Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Black Diamond Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Black Diamond Therapeutics Inc (BDTX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Capital Indonesia Tbk
JK:BACA
|
0.445x |
|
Schwager
SN:SCHWAGER
|
0.113x |
|
Westag & Getalit ST O.N.
F:WUG
|
0.015x |
|
LINMON MEDIA LTD -000025
F:8MN
|
N/A |
|
Economic Investment Trust Ltd
TO:EVT
|
0.095x |
|
Taseco Air Services JSC
VN:AST
|
0.091x |
|
AVATION PLC LS-01
F:9K0
|
N/A |
|
Themis Medicare Limited
NSE:THEMISMED
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Black Diamond Therapeutics Inc from 2017 to 2025. Review Black Diamond Therapeutics Inc (BDTX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.21 Million | $29.61 Million | 0.264x | +135.28% |
| 2024-12-31 | $83.28 Million | $-62.30 Million | -0.748x | -30.89% |
| 2023-12-31 | $116.74 Million | $-66.72 Million | -0.572x | +22.28% |
| 2022-12-31 | $115.69 Million | $-85.08 Million | -0.735x | -43.85% |
| 2021-12-31 | $195.90 Million | $-100.15 Million | -0.511x | -201.71% |
| 2020-12-31 | $307.76 Million | $-52.15 Million | -0.169x | -132.38% |
| 2019-12-31 | $-47.16 Million | $-24.67 Million | 0.523x | -3.81% |
| 2018-12-31 | $-15.54 Million | $-8.45 Million | 0.544x | +54.44% |
| 2017-12-31 | $-6.67 Million | $-2.35 Million | 0.352x | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more